Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).
作者信息
Wijesingha Naomi, Kotecha Aachal, Margaron Philippe, Sivaprasad Sobha
机构信息
UCL Institute of Ophthalmology, London, UK.
Moorfields Eye Hospital NHS Foundation Trust, London, UK.
出版信息
Eye (Lond). 2024 Dec;38(18):3610. doi: 10.1038/s41433-024-03309-5.
Abstract
摘要
相似文献
1
Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).更正：信息图：玻璃体内注射法西单抗采用治疗并延长给药方案长达16周治疗新生血管性年龄相关性黄斑变性的2年疗效、持久性和安全性（TENAYA和LUCERNE的汇总结果）
Eye (Lond). 2024 Dec;38(18):3610. doi: 10.1038/s41433-024-03309-5.
2
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.泰尼雅和卢塞恩：贝伐珠单抗生物类似药 faricimab 在湿性年龄相关性黄斑变性 2 年治疗和延长给药的 3 期临床试验的 2 年结果。
Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19.
3
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.faricimab 每 16 周给药治疗新生血管性年龄相关性黄斑变性患者的疗效、持久性和安全性：III 期 TENAYA 试验日本亚组的 2 年结果。
Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2439-2448. doi: 10.1007/s00417-024-06377-1. Epub 2024 Mar 14.
4
Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).信息图：玻璃体内注射法西单抗在新生血管性年龄相关性黄斑变性中采用治疗并延长给药方案长达16周的2年疗效、持久性和安全性（TENAYA和LUCERNE的汇总结果）
Eye (Lond). 2025 Feb;39(Suppl 1):186-187. doi: 10.1038/s41433-024-03209-8. Epub 2024 Jul 10.
5
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.玻璃体腔内 faricimab 每 16 周治疗新生血管性年龄相关性黄斑变性的疗效、持久性和安全性（TENAYA 和 LUCERNE）：两项随机、双盲、3 期、非劣效性试验。
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
6
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.Faricimab 每 16 周给药治疗新生血管性年龄相关性黄斑变性患者的疗效、持久性和安全性：III 期 TENAYA 试验日本亚组的 1 年结果。
Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11.
7
Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.法西单抗治疗亚洲国家新生血管性年龄相关性黄斑变性患者的疗效、持久性和安全性：TENAYA和LUCERNE试验的1年亚组分析
Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9.
8
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.泰纳亚和卢塞恩：法西单抗治疗新生血管性年龄相关性黄斑变性3期临床试验的基本原理与设计
Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec.
9
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.法西单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿：从临床前研究到 3 期结果。
Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3437-3451. doi: 10.1007/s00417-024-06531-9. Epub 2024 Jun 7.
10
Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE).信息图：玻璃体内注射faricimab每16周一次治疗新生血管性年龄相关性黄斑变性的疗效、持久性和安全性（TENAYA和LUCERNE研究）
Eye (Lond). 2024 Aug;38(Suppl 2):53-54. doi: 10.1038/s41433-023-02867-4. Epub 2023 Dec 20.
Zotero 插件